SKYRIZI Receives FDA Approval for Pediatric Patients with Psoriasis

FDA Approves SKYRIZI for Pediatric Use

AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has granted approval for SKYRIZI® (risankizumab-rzaa) as a treatment option for pediatric patients aged six years and above diagnosed with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This marks a significant milestone in the management of these chronic conditions, especially for children who often experience the physical and emotional burdens associated with them.

New Treatment Options for Young Patients

The approval of SKYRIZI includes a newly formulated 55 mg pre-filled syringe designed specifically for patients weighing less than 40 kg. This is part of AbbVie's commitment to providing tailored treatment solutions that ensure effective management of symptoms in young patients. The standard 150 mg pre-filled syringe and pen are still available for patients weighing 40 kg or more.

Dr. Roopal Thakkar, the executive vice president at AbbVie, emphasizes that psoriasis and psoriatic arthritis can deeply impact numerous aspects of a child's life, making this new treatment option critical for improving their quality of life. With approximately 30% of individuals experiencing the onset of psoriasis before reaching 18 years of age, the approval of SKYRIZI for pediatric patients opens new avenues for effective care.

Understanding Psoriasis and Psoriatic Arthritis in Childhood

Current statistics reveal that annually around 20,000 children under the age of ten are diagnosed with psoriasis in the United States, alongside approximately 14,000 cases of psoriatic arthritis impacting young patients. These conditions manifest not just physically but can disrupt daily activities such as school and play, imposing significant challenges on both the children and their families.

According to Leah M. Howard, CEO of the National Psoriasis Foundation, the emotional toll of living with a chronic disease can heavily influence a child’s formative years. This latest advancement in treatment provides hope and additional options for families navigating these challenging circumstances.

Clinical Support and Efficacy Data

The FDA's approval is supported by findings from the Phase 3 clinical trial program known as OptIMMize. This included multiple assessments that demonstrated the safety and efficacy of SKYRIZI in pediatric patients. Notably, the studies reported clinically meaningful improvements in clinical response rates among children receiving treatment, which were maintained with ongoing therapy.

Dr. Amy S. Paller, an influential researcher and dermatologist, highlighted that the data underlines the treatment's potential for yielding significant positive outcomes. Continued management of psoriasis and psoriatic arthritis not only helps alleviate physical symptoms but also contributes to a child's emotional well-being.

Accessibility and Patient Support Initiatives

AbbVie is dedicated to ensuring that patients have access to SKYRIZI alongside additional support programs. They offer a co-pay card reducing out-of-pocket expenses for eligible patients, and for individuals without insurance, the myAbbVie Assist program provides the medication at no charge to those who qualify.

Conclusion

The FDA's approval of SKYRIZI for pediatric patients is a monumental step toward bolstering the treatment landscape for chronic autoimmune diseases in children. By expanding access to effective therapies, AbbVie aims to improve disease management for young patients while enhancing their overall quality of life. As more innovations arise, hope grows for both patients and families affected by these challenging conditions.